摘要：目的 探讨总前列腺相关抗原(TPSA)、游离前列腺相关抗原(FPSA) 、FPSA/TPSA比值和铁蛋白单独检测和联合检测对于前列腺癌的诊断价值。方法 检测94例前列腺癌组患者、103例前列腺增生组患者和104名对照组血清TPSA、FPSA和Ferr的含量。结果 TPSA、FPSA、FPSA/TPSA和Ferr中，作为单独区分前列腺增生（BPH）和前列腺癌(PCA)最好指标为FPSA/TPSA，诊断灵敏性和特异性分别为82.3%和59.8%；最差的为FPSA，诊断灵敏性和特异性分别为69.3%和52.1%。单独指标区分诊断能力难以同时满足临床灵敏性和特异性的需要；利用二元Logistic回归分析FPSA、TPSA、FPSA/TPSA和Ferr的联合检测，灵敏性和特异性分别为72.6%和79.8%。结论 TPSA、FPSA、FPSA/TPSA和Ferr的联合检测可提高对BPH和PCA的诊断价值，可作为辅助诊断方法应用于临床。

Abstract: Objective To explore the clinical value of determination of the total prostate-associated antigen (TPSA), free prostate-associated antigen (FPSA), FPSA/TPSA ratio and ferritin alone and jointly for prostate cancer. Methods The concentration of TPSA, FPSA, ferritin and FPSA / TPSA were detected in 94 prostate cancer patients, 103 benign prostatic hyperplasia patients and 104 healthy controls. Results When the TPSA, FPSA, FPSA/TPSA and Ferr were detected alone to differentiate the benign prostatic hyperplasia and prostate cancer, the best diagnostic indicator was FPSA / TPSA. The diagnostic sensitivity and specificity were 82.3% and 59.8%, respectively. The worst was FPSA, the diagnostic sensitivity and specificity were 69.3% and 52.1%, respectively. When the indicators were used alone for the distinction between PCA and BPH, the diagnostic value cannot meet the clinical need. Binary logistic regression analysis was used for the FPSA, TPSA, FPSA / TPSA and ferritin joint diagnosis. The diagnostic value was greater than that by any indicator alone, the diagnostic sensitivity and specificity were 72.6%and 79.8%, respectively. Conclusion The joint detection of TPSA, FPSA, FPSA/TPSA and Ferritin could improve the diagnostic value, and can be served as an aided diagnosis method for clinical application.